Literature DB >> 17005805

Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental Chlamydophila pneumoniae infection.

Dario Caronzolo1, Valeria Lucini, Marilou Pannacci, Silvia Grosso, Nelly Kieffer, Lorenzo Bello, Andreas Bikfalvi, Francesco Scaglione.   

Abstract

Chlamydophila pneumoniae is a pathogen that is involved in acute and chronic respiratory infections and that is associated with asthma and coronary artery diseases. In this study, we evaluated the effects of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, against experimental infections caused by C. pneumoniae. Moreover, we investigated the relationships between C. pneumoniae and alpha(v)beta(3) integrin functions in order to explain the possible mechanism of action of PEX both in vitro and in vivo. For the in vitro experiments, HeLa cells were infected with C. pneumoniae and treated with either PEX or azithromycin. The results obtained with PEX were not significantly different (P > 0.05) from those achieved with azithromycin. Similar results were also obtained in a lung infection model. Male C57BL/J6 mice inoculated intranasally with 10(6) inclusion-forming units of C. pneumoniae were treated with either PEX or azithromycin plus rifampin. Infected mice treated with PEX showed a marked decrease in C. pneumoniae counts versus those for the controls; this finding did not differ significantly (P > 0.05) from the results observed for the antibiotic-treated group. Integrin alpha(v)beta(3) plays an important role in C. pneumoniae infection. Blockage of integrin activation led to a significant inhibition of C. pneumoniae infection in HeLa cells. Moreover, CHO(DHFR) alpha(v)beta(3)-expressing cells were significantly (P < 0.001) more susceptible to C. pneumoniae infection than CHO(DHFR) cells. These results offer new perspectives on the treatment of C. pneumoniae infection and indicate that alpha(v)beta(3) could be a promising target for new agents developed for activity against this pathogen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005805      PMCID: PMC1610071          DOI: 10.1128/AAC.00108-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

2.  Epithelial cells infected with Chlamydophila pneumoniae (Chlamydia pneumoniae) are resistant to apoptosis.

Authors:  K Rajalingam; H Al-Younes; A Müller; T F Meyer; A J Szczepek; T Rudel
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 3.  Get a ligand, get a life: integrins, signaling and cell survival.

Authors:  Dwayne G Stupack; David A Cheresh
Journal:  J Cell Sci       Date:  2002-10-01       Impact factor: 5.285

4.  Trypanosoma cruzi infection inhibited by peptides modeled from a fibronectin cell attachment domain.

Authors:  M A Ouaissi; J Cornette; D Afchain; A Capron; H Gras-Masse; A Tartar
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

5.  Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

6.  Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.

Authors:  L Bello; G Carrabba; C Giussani; V Lucini; F Cerutti; F Scaglione; J Landré; M Pluderi; G Tomei; R Villani; R S Carroll; P M Black; A Bikfalvi
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis.

Authors:  Nadia Al-Fakhri; Jochen Wilhelm; Meinhard Hahn; Martin Heidt; Friedrich W Hehrlein; Andrea M Endisch; Thomas Hupp; Sanjay M Cherian; Yuri V Bobryshev; Reginald S A Lord; Norbert Katz
Journal:  J Cell Biochem       Date:  2003-07-01       Impact factor: 4.429

9.  Lipid rafts, caveolae, caveolin-1, and entry by Chlamydiae into host cells.

Authors:  Elizabeth S Stuart; Wilmore C Webley; Leonard C Norkin
Journal:  Exp Cell Res       Date:  2003-07-01       Impact factor: 3.905

10.  Fibronectin tetrapeptide is target for syphilis spirochete cytadherence.

Authors:  D D Thomas; J B Baseman; J F Alderete
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.